Fertility News and Research

RSS

Brdt protein in developing sperm cells direct tight re-packaging of sperm DNA

In the quest for speed, olympic swimmers shave themselves or squeeze into high-tech super-suits. In the body, sperm are the only cells that swim and, as speed is crucial to fertility, have developed their own ways to become exceptionally streamlined. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Grenoble, the Institut de Biologie Structurale (IBS) and the Institut Albert Bonniot, both also in Grenoble, have been studying the secrets of speedy sperm.

1 Oct 2009

Incept BioSystems commences human clinical trial of its SMART Embryo Culture System

Incept BioSystems, Inc., a privately-held biomedical device company using patented microfluidic technology developed at the University of Michigan, announced today that it has initiated the first U.S. human clinical trial of its proprietary SMART Embryo Culture System. The microscale SMART technology platform is designed to improve the in vitro manipulation, performance, and viability of embryos for the treatment of patients undergoing in vitro fertilization (IVF).

1 Oct 2009

Swemed Sense oocyte aspiration needle available now for Australian customers

“Swemed Sense, with its unique characteristics, is an important part of our existing product portfolio in Europe, and is now available even to our Australian customers, Says Vitrolife's Vice President of Marketing and Sales, Nils Sellbom. Vitrolife have identified Australia as one of the key markets in the world and we have a office located in Melbourne. Approximately 67 000 fertility treatment cycles are conducted in Australia and New Zealand each year”

1 Oct 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

AFA reacts to an Ohio woman's claims of an embroyo mix up

An Ohio woman, 40-year-old Carolyn Savage, claims a fertility clinic implanted the wrong embryo and that the baby she's due to deliver the first week in October is not hers. Several media reports state Savage and her husband plan to give the baby boy to his biological parents. The name of the clinic is not being released in this very rare alleged case.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Women usually tightlipped about bladder problems

Women may be known as the more talkative sex, but when it comes to a certain sensitive health topic, their lips are sealed, according to a new "Bladder Talk" survey of 780 women aged 35 and older in North America (U.S. and Canada) sponsored by TENA(R), the worldwide leader in the management of bladder protection, and conducted by Harris Interactive.

24 Sep 2009

Utah medical ethics expert chairs NIH review of embryonic cells

University of Utah medical ethics expert Jeffrey R. Botkin will chair a federal panel that will review scientists' requests to conduct government-funded research using embryonic stem cells left over from couples who used "test-tube fertilization" to have babies.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

PROLOR Biotech initiates Phase I clinical trial of its human growth hormone drug candidate

PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced the initiation of a Phase I clinical trial of its long-acting human growth hormone drug candidate hGH-CTP.

21 Sep 2009

Two-day forum addresses maternal, child mortality in Asia-Pacific region

Poor health care, gender inequality, violence and poverty are to blame for Asian-Pacific countries' failure to significantly reduce maternal and child mortality rates in the region, Noeleen Heyzer, executive secretary of the Economic and Social Commission for Asia and the Pacific (ESCAP), said during the Asia-Pacific Forum on International Conference on Population and Development in Bangkok.

18 Sep 2009

Health reform bill may limit tax-free flexible spending accounts

NASDAQ/Dow Jones reports: "Employees who enjoy unlimited tax-free treatment of out-of-pocket medical expenses through employee-benefit plans could be facing new curbs on the tax subsidy in health-care overhaul legislation.

17 Sep 2009

ESHRE's workshop on cryobiology

ESHRE invites you to attend its workshop on freezing of human sperm, eggs and embryos in Athens, Greece "Cryobiology and cryopreservation of human gametes and embryos". The workshop provides a forum for clinicians and scientists to share research results and discuss problems and new developments.

17 Sep 2009

ESHRE's first workshop on male infertility

ESHRE invites you to attend its first workshop on male infertility in Thessaloniki, Greece "Reproductive andrology: linking laboratory to clinical practice". The workshop provides a forum for clinicians and scientists to share research results and discuss new developments.

16 Sep 2009

ESHRE workshop on human reproduction, more specifically on the freezing of sperm and embryos

ESHRE invites you to attend its workshop on freezing of human sperm, eggs and embryos in Athens, Greece "Cryobiology and cryopreservation of human gametes and embryos".

16 Sep 2009

Defective gene is linked to male infertility

Virginia Commonwealth University School of Medicine researchers have discovered a gene involved with the production of sperm that may contribute to male infertility and lead to new approaches to male contraception.

16 Sep 2009

IntegraMed’s Attain IVF Program now offered at Dallas IVF

IntegraMed America, Inc. (NASDAQ: INMD), the nation’s leading provider of specialty healthcare services in emerging, technology-focused niches, today announced that Dallas IVF has begun offering IntegraMed’s Attain™ IVF Program, a course-of-treatment financing program that improves patient success rates with in vitro fertilization (IVF) fertility treatments.

14 Sep 2009